2025 Biosimilars Diabetes 
Express Pharma
JUNE 26, 2025
Biocon Biologics (BBL), a biosimilars company and subsidiary of Biocon, has announced that Health Canada has granted a Notice of Compliance (NOC) for YESAFILI (aflibercept), a biosimilar to EYLEA (aflibercept) injection. mL, and was granted on 26 June 2025. The company has scheduled the product’s Canadian launch for 4 July 2025.
STAT
SEPTEMBER 23, 2022
Market share is often held up as the most relevant metric for the success of a biosimilar class. I believe there are other metrics, like cost savings or signs of greater patient access, that should also be used to define biosimilars’ successes or failures. the first biosimilar was launched in September 2015. In the U.S.,
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Big Molecule Watch
JULY 3, 2025
In its June 2025 meeting, the European Medicines Agency’s (“EMA”) Committee for Medicinal Products for Human Use (“CHMP”) adopted positive opinions for six biosimilar medicines. Additionally, on June 23, 2025, Alvotech announced that the EMA adopted a positive opinion recommending market approval of AVT06.
PharmaVoice
JUNE 23, 2025
Published June 23, 2025 Amy Baxter Staff Reporter post share post print email license Stock via Getty Images Listen to the article 6 min This audio is auto-generated. Mounjaro reached nearly $12 billion in revenue last year, while Jardiance, Lilly’s diabetes medication co-owned with Boehringer Ingelheim, topped $10 billion for the year.
Drug Patent Watch
JANUARY 13, 2025
Biosimilars have emerged as a game-changing force, promising to revolutionize patient access to life-saving biologics while simultaneously reducing healthcare costs. ”[1] The global biosimilars market is experiencing exponential growth, with projections indicating it will reach $69.4 billion by 2025, growing at a CAGR of 34.2%
Pharmaceutical Technology
JUNE 23, 2025
Robert Barrie June 23, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Bayer’s Eylea is a heavyweight of the ophthalmic drug landscape, approved for a range of eye diseases. Go deeper with GlobalData Reports LOA and PTSR Model - Aflibercept Biosimilar in Age Related Macular. CucuMberStudio via Shutterstock.
Express Pharma
MARCH 16, 2025
To move from generics to novel drug development, Indian companies must invest heavily in R&D for innovative therapies like biosimilars, cell and gene therapies, and specialty drugs. Similarly, Dr. Reddy’s and Cipla are exploring the biosimilar and complex generics space, focusing on areas like respiratory and oncology drugs.
Expert insights. Personalized for you.
91 
Let's personalize your content